Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06242470 · ClinicalTrials.gov registry record · Phase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by MacroGenics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 12
- Study locations
NCT06242470 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by MacroGenics. The registered enrollment target is 250 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT06242470, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by MacroGenics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 12
- Study locations
Study Summary
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
Conditions Studied
Interventions
- BIOLOGICAL MGC026 Dose Escalation
- BIOLOGICAL MGC026 Dose for Expansion
Study Locations (12)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas Health Science Center at Houston - Houston
Other
- Oxford University Hospitals NHS Foundation Trust - Oxford
- The Royal Marsden NHS Foundation Trust - Sutton
California
- The Angeles Clinic and Research Institute - Los Angeles
Michigan
- START Midwest - Grand Rapids
New York
- START-New York Long Island - Lake Success
Oregon
- Providence Cancer Institute - Portland
Utah
- START Mountain Region - West Valley City
Queensland
- ICON Cancer Centre Wesley - Auchenflower
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06242470
The ClinicalTrials.gov registry entry for NCT06242470 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which MGC026 Dose Escalation is the first listed.
NCT06242470 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT06242470 about?
NCT06242470 is a clinical study titled "A Study of MGC026 in Participants With Advanced Solid Tumors". The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort exp...
What is the current status of trial NCT06242470?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-03-06. Estimated completion is 2028-10.
What conditions does trial NCT06242470 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Advanced Solid Tumor, Endometrial Cancer, Bladder Cancer.
What interventions are being tested in trial NCT06242470?
The interventions under investigation include: MGC026 Dose Escalation (BIOLOGICAL), MGC026 Dose for Expansion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06242470?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06242470 being conducted?
This trial has 12 study locations across California, Michigan, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.